201. Neutrophil-to-lymphocyte ratio correlates with prognosis and response to chemotherapy in patients with non-M3 de novo acute myeloid leukemia
- Author
-
Yiyi Zhu, Kang Yu, Rongrong Chen, Kanchun Dai, Yiqin Weng, Ziyang Huang, Qianqian Yang, Qianying Zhang, Songfu Jiang, and Shenghui Zhang
- Subjects
Cancer Research ,Chemotherapy ,business.industry ,medicine.medical_treatment ,fungi ,De novo acute ,Myeloid leukemia ,overall survival (OS) ,disease-free survival (DFS) ,Oncology ,hemic and lymphatic diseases ,neutrophil-to-lymphocyte ratio (NLR ratio) ,Acute myeloid leukemia (AML) ,Cancer research ,Medicine ,Original Article ,Radiology, Nuclear Medicine and imaging ,In patient ,Neutrophil to lymphocyte ratio ,business - Abstract
Background Neutrophil-to-lymphocyte (NLR) ratio can predict survival outcome and assess response to chemotherapy in several tumors. However, the values of NLR in acute myeloid leukemia (AML) remains unknown. Methods A retrospective review of 181 patients with de novo AML excluding acute promyelocytic leukemia (M3) was conducted in our institute. We categorized the patients into two groups by defining NLR =2.0 as the cut-off point. NLR was calculated by the ratio of the number of neutrophils to lymphocytes in the peripheral blood (PB). The baseline clinicopathologic parameters were compared using Chi-squared test or Kruskal-Wallis H test. Kaplan-Meier analysis was used to assess survival, and overall survival (OS) and disease-free survival (DFS) were analyzed using the Cox regression with log-rank tests. Results We found AML patients with low NLR (
- Published
- 2021
- Full Text
- View/download PDF